Rapport Therapeutics (RAPP) EBITDA Margin (2026)
Rapport Therapeutics' (RAPP) quarterly EBITDA Margin came in at 121.08% in Q1 2026.
Rapport Therapeutics (RAPP) EBITDA Margin (2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 1 years of EBITDA Margin data on file, last reported at 121.08% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Rapport Therapeutics | 1.94 Bn | 1.94 Bn | - | -121.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121.08% |